Recent Development of Nuclear Molecular Imaging in Thyroid Cancer.

Huiting Liu, Xiaoqin Wang, Ran Yang, Wenbing Zeng, Dong Peng, Jason Li, Hu Wang

Journal: BioMed research international 2019;2018():2149532

PMID: 29951528

Abstract

Therapies targeting specific tumor pathways are easy to enter the clinic. To monitor molecular changes, cellular processes, and tumor microenvironment, molecular imaging is becoming the key technology for personalized medicine because of its high efficacy and low side effects. Thyroid cancer is the most common endocrine malignancy, and its theranostic radioiodine has been widely used to diagnose or treat differentiated thyroid cancer. This article summarizes recent development of molecular imaging in thyroid cancer, which may accelerate the development of personalized thyroid cancer therapy.

Address: Department of Nuclear Medicine, Chongqing Three Gorges Central Hospital, Wanzhou 404000, China.; Clinical Test Center, Chongqing Three Gorges Central Hospital, Wanzhou 404000, China.; Department of Radiology, Chongqing Three Gorges Central Hospital, Wanzhou 404000, China.; Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.; Medical School, China Three Gorges University, Yichang 443002, China.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.